Related Experiment Video
Updated: Oct 3, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan
Abstract:
We report a retrospective analysis of children with myelodysplastic syndrome (MDS) diagnosed between 1990 and 1997 in Japan. In total, 189 patients were enrolled: 122 cases of primary MDS (26 RA, 18 RAEB, 25 RAEBt, 53 CMML/JMML), 24 cases with constitutional predisposition to MDS, and 43 cases of therapy-related MDS (t-MDS). The frequency of pediatric MDS was estimated to be 7.7% of all leukemias. Cytogenetic abnormalities were observed in 41% of primary MDS and 90% of t-MDS cases. The 4-year survival rate, estimated by Kaplan-Meier analysis, for primary RA was 78.9%, while other types of MDS and JMML had rates lower than 40%, and t-MDS showed an even more unfavorable prognosis. In primary MDS, the survival rate of patients with cytogenetic abnormalities was significantly lower. Among prognostic variables by IPSS, only the cytogenetic pattern was useful for predicting outcome in childhood MDS. There was no apparent advantage to chemotherapy for RA, and the survival rate in patients with primary RA, JMML, or t-MDS receiving stem cell transplantation was significantly higher. More precise designs of our diagnostic and classification systems, as well as therapeutic trials in large-scale prospective studies, are necessary for further improvements in MDS outcome.
Insights
This study analyzed pediatric myelodysplastic syndromes (MDS) in Japan, finding varied survival rates and the importance of cytogenetic patterns for prognosis. Stem cell transplantation improved outcomes for certain MDS types.
Area of Science:
- Hematology
- Pediatric Oncology
- Clinical Genetics
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Pediatric MDS is rare, with distinct characteristics compared to adult forms.
- Understanding prognostic factors is crucial for improving outcomes in childhood MDS.
Purpose of the Study:
- To analyze the characteristics and outcomes of pediatric myelodysplastic syndromes (MDS) diagnosed in Japan.
- To evaluate the impact of cytogenetic abnormalities and treatment modalities on survival rates.
- To identify prognostic variables for childhood MDS.
Main Methods:
- Retrospective analysis of 189 pediatric patients diagnosed with MDS between 1990 and 1997.
- Classification into primary MDS, constitutional predisposition, and therapy-related MDS (t-MDS).
- Kaplan-Meier survival analysis and evaluation of prognostic variables (IPSS).
Main Results:
- Cytogenetic abnormalities were present in 41% of primary MDS and 90% of t-MDS.
- Four-year survival rates varied significantly: 78.9% for primary RA, <40% for other MDS/JMML, and poorer for t-MDS.
- Cytogenetic abnormalities correlated with significantly lower survival in primary MDS.
- Stem cell transplantation showed improved survival for primary RA, JMML, and t-MDS.
Conclusions:
- Cytogenetic pattern is a key prognostic factor in childhood MDS.
- Chemotherapy offered no clear benefit for RA.
- Stem cell transplantation is a potentially effective treatment for specific pediatric MDS subtypes.
- Further large-scale prospective studies are needed to refine diagnostic criteria and therapeutic strategies.
